Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MAP2K1 |
| Variant | Q56_G61delinsR |
| Impact List | indel |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | MAP2K1 Q56_G61delinsR results in a deletion of six amino acids of the Map2k1 protein from amino acids 56 to 61, combined with the insertion of an arginine (R) at the same site (UniProt.org). Q56_G61delinsR results in proliferation under low serum conditions similar to wild-type Map2k1 in a competition assay, however, is predicted to lead to a gain of Map2k1 protein function as demonstrated by increased proliferation in a competition assay in normal serum and increased transformation activity in cultured cells, and confers resistance to Mek and Braf inhibitors in the context of BRAF V600E in culture (PMID: 36442478). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 Q56_G61delinsR |
| Transcript | NM_002755.4 |
| gDNA | chr15:g.66435113_66435127del15 |
| cDNA | c.167_181del15 |
| Protein | p.Q56_G61delinsR |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017022411.2 | chr15:g.66435113_66435127del15 | c.167_181del15 | p.Q56_G61delinsR | RefSeq | GRCh38/hg38 |
| XM_017022411.3 | chr15:g.66435113_66435127del15 | c.167_181del15 | p.Q56_G61delinsR | RefSeq | GRCh38/hg38 |
| NM_002755.4 | chr15:g.66435113_66435127del15 | c.167_181del15 | p.Q56_G61delinsR | RefSeq | GRCh38/hg38 |
| NM_002755.3 | chr15:g.66435113_66435127del15 | c.167_181del15 | p.Q56_G61delinsR | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 Q56_G61delinsR | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 Q56_G61delinsR in culture (PMID: 36442478). | 36442478 |